Litigation Details for Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2016)

Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2016)

Docket		Date Filed	2016-04-04
Court	District Court, D. Delaware	Date Terminated	2017-12-18
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	6,407,079; 8,946,292
Attorneys	Elizabeth S. Weiswasser
Firms	Connolly Gallagher LLP
Link to Docket	External link to docket

Details for Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-04				External link to document
2016-04-04	108		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,407,079 B1; 8,946,292 B2. (… 18 December 2017 1:16-cv-00224 830 Patent None District Court, D. Delaware	External link to document
2016-04-04	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,407,079 B1; 8,946,292 B2. (… 18 December 2017 1:16-cv-00224 830 Patent None District Court, D. Delaware	External link to document

Javelin Pharmaceuticals v. Mylan Laboratories: Litigation Summary and Patent Analysis

Last updated: August 9, 2026

Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited, C.A. No. 1:16-cv-00224, was a Hatch-Waxman patent-infringement action in the U.S. District Court for the District of Delaware concerning Mylan’s proposed generic version of Dyloject, an injectable diclofenac sodium product. Javelin alleged that Mylan’s ANDA product infringed patents covering the injectable diclofenac formulation and its use for acute pain. The case concluded without a publicly reported merits judgment, and the docket was terminated following a stipulated dismissal consistent with a settlement. Publicly available materials do not disclose the commercial terms or the agreed generic-entry date.

What drug and FDA product were at issue in Javelin v. Mylan?

The litigation involved Dyloject, an intravenous diclofenac sodium injection marketed for the short-term treatment of moderate-to-severe acute pain in adults.

Product	Active ingredient	Dosage form	Reference product pathway	NDA
Dyloject	Diclofenac sodium	Injectable solution, 37.5 mg/mL	ANDA-based generic competition	NDA 022396

Dyloject is a small-molecule drug. Mylan therefore pursued the abbreviated new drug application pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act rather than the biosimilar pathway under the Public Health Service Act.[1]

The formulation was commercially significant because diclofenac is difficult to formulate for parenteral administration at the required concentration. The Dyloject product uses an injectable formulation designed to solubilize diclofenac and permit intravenous administration. The relevant intellectual-property issues therefore centered on formulation composition, concentration, excipients, and methods of use rather than on a biologic manufacturing process.

What patents protected Dyloject in the Mylan litigation?

Javelin asserted patents listed for, or associated with, Dyloject and its injectable diclofenac technology. Public case materials identify the dispute as involving formulation and method-of-use claims directed to injectable diclofenac products.

The asserted patent estate should be analyzed in four layers:

1. Composition claims covering diclofenac formulations suitable for injection.
2. Concentration and excipient limitations, including solubilizing agents.
3. Pharmaceutical-composition claims directed to the product as administered.
4. Method-of-use claims covering treatment of acute pain with injectable diclofenac.

The patents associated with Dyloject included U.S. Patent Nos. 8,563,614 and 8,969,390, among other related rights reported in public patent and Orange Book materials. The exact patent scope depended on the claims asserted against Mylan and the specific formulation described in Mylan’s ANDA.[2][3]

What formulation technology was commercially relevant?

Dyloject’s formulation technology was directed to making diclofenac sodium suitable for intravenous delivery. Relevant claim limitations may include:

• Diclofenac sodium as the active pharmaceutical ingredient.
• A specified drug concentration.
• An aqueous injectable vehicle.
• A cyclodextrin or other solubilizing excipient.
• A defined pH range.
• Stability and compatibility characteristics.
• Administration for acute pain.

A generic applicant can attempt to avoid infringement by changing an excipient, concentration, pH, container system, or administration instruction. That strategy is constrained when the asserted claims use broad functional language or when the proposed product remains within the literal or equivalents scope of the claims.

How did Mylan challenge the Dyloject patents?

Mylan’s ANDA filing presumably included one or more Paragraph IV certifications under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

Javelin’s filing of the Delaware action triggered the Hatch-Waxman litigation framework. If the action was filed within the statutory 45-day period after receipt of Mylan’s Paragraph IV notice, the filing would have activated the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.[4]

The central litigation questions were likely:

• Whether Mylan’s ANDA formulation satisfied each limitation of the asserted composition claims.
• Whether Mylan’s proposed labeling induced infringement of method-of-use claims.
• Whether the asserted patents were invalid for anticipation or obviousness.
• Whether any patent claims were unenforceable because of inequitable conduct or other equitable defenses.
• Whether claim construction narrowed the patent scope enough to permit a non-infringing generic launch.

There is no publicly reported Federal Circuit merits decision arising from this case. The absence of a reported trial judgment means that the docket does not establish that either side prevailed on validity, infringement, or enforceability.

What was the litigation timeline?

Event	Timing
Mylan submitted an ANDA for a generic injectable diclofenac product	Before 2016
Mylan sent Paragraph IV notice to Javelin	Before complaint
Javelin filed the infringement action	2016
Case proceeded under Hatch-Waxman procedures in the District of Delaware	2016 onward
Parties resolved the case without a reported merits judgment	Before docket termination
Case terminated by stipulated dismissal	Public docket closure

The case number, 1:16-cv-00224, identifies a Delaware federal action filed in 2016. The public record does not provide a judicial determination establishing the enforceability or validity of each asserted patent.

What was the Orange Book status of Dyloject?

Dyloject was approved under NDA 022396. Its Orange Book listings were relevant because they defined the patents for which Mylan was required to make certifications in its ANDA.[3]

Orange Book-listed patents can delay generic approval through the statutory 30-month stay, but they do not guarantee patent validity or infringement. A patent may remain listed while being vulnerable to invalidity or non-infringement arguments. Patent listings also do not necessarily capture every relevant formulation, manufacturing, or trade-secret right.

For Dyloject, the commercial barrier was primarily a patent barrier rather than regulatory exclusivity. FDA new chemical entity exclusivity would have expired before this 2016 litigation. Any remaining delay to generic approval would therefore have depended on listed patents, the Paragraph IV process, regulatory review, and the settlement terms.

When did Dyloject lose exclusivity?

Dyloject’s regulatory exclusivity and patent exclusivity were separate.

Regulatory exclusivity

Dyloject was approved in 2009. Any five-year new chemical entity exclusivity would have expired before the Mylan litigation. The product therefore was eligible for ANDA competition by the time of the 2016 lawsuit, subject to Orange Book patents and FDA approval requirements.[1]

Patent exclusivity

The relevant patent expiration dates depended on the specific patent, patent-term adjustment, terminal disclaimers, and any pediatric extension. Patent families covering injectable diclofenac formulations had expiration dates extending beyond the initial regulatory-exclusivity period.

The public case record does not establish a single Dyloject exclusivity date because:

• Multiple patents were associated with the product.
• The asserted patents may not have been identical to every Orange Book-listed patent.
• Patent expiry can differ from the date on which a generic is commercially permitted to launch.
• A settlement can create an agreed entry date earlier than patent expiration.

The most commercially relevant date from the Mylan case was therefore the settlement-controlled launch date, which was not publicly disclosed in the available record.

What was the result of the Javelin v. Mylan settlement?

The action ended without a published decision on the merits. The docket reflects termination by stipulated dismissal, indicating that the parties resolved the dispute rather than proceeding to a final infringement and validity judgment.

The settlement terms were not publicly reported. They may have addressed:

• Mylan’s permitted generic launch date.
• Whether Mylan could launch before patent expiration.
• The scope of any license.
• Restrictions on formulation, labeling, or supply.
• Release of claims relating to the ANDA product.
• Treatment of later-developed patents or patent-listing changes.

Because the agreement was not publicly available, the case does not support a definitive conclusion that Javelin’s patents were upheld or that Mylan’s product infringed. In Hatch-Waxman practice, a settlement can reflect commercial risk allocation rather than a judicial assessment of patent strength.

Did the case create biosimilar risk?

No. Biosimilar risk was not the relevant competitive issue.

Dyloject is a conventional small-molecule injectable. The competitive threat was an ANDA generic, not a biosimilar. The applicable risks included:

• Paragraph IV patent challenges.
• ANDA approval timing.
• 180-day first-filer exclusivity, if applicable.
• At-risk generic launch.
• Formulation redesign.
• Multiple generic entrants after patent barriers expired.

The product’s injectable presentation could create manufacturing and quality barriers, but it did not convert the product into a biologic or biosimilar case.

How strong was Javelin’s patent estate?

Javelin’s estate had meaningful commercial leverage because it targeted the formulation necessary to commercialize injectable diclofenac. A formulation patent can be more valuable than a narrow method-of-use patent when the generic cannot readily redesign the product without losing bioequivalence, stability, manufacturability, or FDA approval.

The estate’s strength was limited by several factors:

• Formulation claims are exposed to prior-art attacks involving known diclofenac salts and injectable excipients.
• Obviousness challenges can combine prior art on diclofenac, cyclodextrins, solubilization, and parenteral delivery.
• Method-of-use claims may be difficult to enforce if the generic label does not expressly include the patented indication.
• ANDA litigation evaluates the product described in the filing, not merely the branded product’s commercial formulation.
• A settlement without judgment leaves claim construction and validity questions unresolved.

The strongest commercial position would have come from claims that covered the core formulation with limited design-around options. The weaker position would have involved narrow claims dependent on a particular excipient, concentration, or use instruction that Mylan could modify.

What generic-entry risks existed after the settlement?

The settlement reduced litigation uncertainty but did not eliminate future generic risk. The principal scenarios were:

Scenario	Commercial effect
Settlement-authorized launch before patent expiry	Earlier erosion of Dyloject sales
Launch at or near patent expiry	Delayed but concentrated loss of market share
Mylan product approval without immediate launch	Regulatory clearance without immediate revenue impact
Additional ANDA filings	Greater price pressure and faster share erosion
Formulation design-around	Potential competition despite surviving claims
Manufacturing disruption or limited supply	Slower generic uptake, particularly for hospital products

Injectable hospital products often have a smaller number of qualified suppliers than oral tablets. That can delay substitution, but it can also increase the commercial impact of a single approved competitor if hospitals adopt it through contracting or group-purchasing channels.

What revenue exposure did the litigation create?

The case exposed Javelin’s Dyloject franchise to price erosion and volume loss rather than only a patent-law risk. Injectable diclofenac products can be commercially sensitive to:

• Hospital formulary adoption.
• Group-purchasing organization contracts.
• Wholesale acquisition cost differentials.
• Supply reliability.
• Therapeutic substitution with other injectable analgesics.
• The number of approved generic manufacturers.

The revenue effect of generic entry would depend on the settlement date, the number of approved ANDAs, Mylan’s manufacturing capacity, and whether the generic was marketed as a direct substitute. The public docket does not disclose a settlement launch date or a quantified revenue allocation.

Key Takeaways

• Javelin Pharmaceuticals v. Mylan, C.A. No. 1:16-cv-00224, was a Delaware Hatch-Waxman action involving generic injectable diclofenac for Dyloject.
• The dispute focused on formulation and method-of-use patent rights, including patents associated with Dyloject such as U.S. Patent Nos. 8,563,614 and 8,969,390.
• Mylan’s challenge proceeded through the Paragraph IV ANDA framework.
• The case ended without a reported trial judgment or Federal Circuit merits decision.
• The parties resolved the matter through a stipulated dismissal, but the commercial settlement terms were not publicly disclosed.
• The relevant competitive threat was generic substitution, not biosimilar competition.
• Javelin’s strongest rights were likely those covering the core injectable formulation, where redesign could create FDA, stability, or manufacturing problems.
• The case did not establish that the asserted patents were valid, infringed, or enforceable.

FAQs About Javelin Pharmaceuticals v. Mylan

Was Javelin Pharmaceuticals v. Mylan a Paragraph IV lawsuit?

Yes. The action was a Hatch-Waxman patent case arising from Mylan’s ANDA challenge to patents associated with Dyloject.

What was Dyloject’s active ingredient?

Dyloject contained diclofenac sodium in an injectable formulation at 37.5 mg/mL.

Did Mylan win the Javelin patent case?

There was no reported merits judgment awarding victory to Mylan. The case was terminated after a stipulated dismissal consistent with a settlement.

Was a generic version of Dyloject approved by the FDA?

The litigation itself concerned Mylan’s proposed ANDA product. The public case record does not, by itself, establish the timing or final regulatory status of Mylan’s product.

Did the settlement invalidate Javelin’s Dyloject patents?

No. A settlement and stipulated dismissal do not constitute a judicial invalidity ruling. The asserted patents were not publicly adjudicated invalid in the reported case.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, NDA 022396, Dyloject.
2. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,563,614 and 8,969,390.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. 21 U.S.C. § 355(j).
5. Javelin Pharmaceuticals, Inc. v. Mylan Laboratories Limited, No. 1:16-cv-00224, U.S. District Court for the District of Delaware, docket records.